CVAT, JNJ, CSRH, MRK, PWRM, MU, DrStockPick.com Stock Report!
Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Friday September 25, 2009
DrStockPick.com Stock Report!
CVAT, JNJ, CSRH, MRK, PWRM, MU
**************************************************************
CSRH, Consorteum Holdings Inc, CSRH.OB
CSRH is a company in the financial services, payment and transaction processing industries.
CSRH provides electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. CSRH’s services provide customized, innovative technology solutions that create, augment and enhance customers’ existing financial, payment and transactional processing systems.
CSRH has established an agreement with a third party partner within the payment processing industry to offer Merchant Discount Rates. Consorteum will leverage this new partnership to offer competitive Merchant Discount Rates and Point of Sale hardware to its new and existing client base.
Quent Rickerby, President & COO of Consorteum Holdings Inc., said, “This agreement will allow Consorteum to offer Canadian clients measurable cost savings on their Credit and Debit Card processing and further enhance the number of products and services we have available.”
Consorteum’s new Merchant Discount Rate program further enhances its list of financial services available to current and future clients. The addition of generating new revenues from debit and credit card transaction processing will ensure long-term revenue growth and incremental residual income. Consorteum will continue to expand its portfolio of financial services, which will further grow the revenues of the company, ensuring increased shareholder value. Processors in North America process in excess of 75 billion electronic payment transactions annually.
More about CSRH at www.consorteum.com
**************************************************************
PWRM, Power 3 Medical Products Inc, PWRM.OB
Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), and Parkinson’s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.
PWRM Announced that its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009
Further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”
More about PWRM at www.power3medical.com
**************************************************************
CVAT, Cavitation Technologies Inc, CVAT.OB
CVAT is a “Green-Tech” company, established in 2006 to become a world leader in the development of new cutting edge technologies for the, vegetable oil refining, renewable fuel, petroleum, water treatment, wastewater sanitation, petroleum, food and beverage, chemical industries.
CVAT announced that Biocombustibles y Energias Alternativas (ALS) has entered into a long-term agreement with CTI (Cavitation Technologies Inc) to develop projects in Argentina and throughout Latin America. ALS (www.alsbio.com), partnering with DOW Chemical (www.dow.com), has identified several projects where CTI technology can greatly improve process yields and profitability using CTI and DOW proprietary technology.
According to Roman Gordon, CTI CEO, “We are very pleased to be working with ALS and DOW on these projects and expect that there is a bright future for the combination of our technologies in Argentina as well as the rest of the world where older outdated technologies have been installed.” Mr. Gordon went on further to say, “We are also very excited about the other applications for our technology in the wastewater, petroleum and chemical industries that DOW could have an interest in. We look forward to working with them. These first projects in Argentina represent 480,000 metric tons of fuel per year and more than a $2,500,000 in sales revenue for CTI.”
CVAT More about CVAT at www.cavitationtechnologies.com
**************************************************************
JNJ, Johnson & Johnson
JNJ engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON’S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names.
JNJ’s McNeil unit is voluntarily recalling 57 lots of infants’ and children’s liquid Tylenol products because of possible bacterial contamination. The products being recalled were made between April and June and include nearly two dozen varieties, including Children’s Tylenol Suspension 4 oz. Grape, Infants’ Tylenol Grape Suspension Drops 1/4 oz. and Children’s Tylenol Plus Cold/Allergy 4 oz. Bubble Gum.
**************************************************************
MRK, Merck & Co., Inc.
MRK provides products for human and animal health in the United States and internationally. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents.
MRK issued the following statement today in response to the U.S. Food and Drug Administration’s (FDA’s) update on JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin).
“Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients. Merck has also carefully reviewed post marketing adverse experience reports, and Merck believes these data do not demonstrate that a causal relationship exists between sitagliptin and pancreatitis. Merck appreciates the important role that the FDA plays in assessing the safety of medicines and, as we do with all of our medicines, we will continue to monitor the safety of JANUVIA and will share the data with regulatory agencies and the medical community,” said John Amatruda, M.D., Senior Vice President and Franchise Head, Diabetes and Obesity, Merck Research Laboratories. “Patients with type 2 diabetes are more likely to develop pancreatitis than other people, and as FDA noted in a publication earlier this year, ‘diagnosis [of drug-induced pancreatitis] poses a challenge since it can be difficult to rule out other causes.’ Merck would encourage any patient with concerns to speak with their physician.”
**************************************************************
MU, Micron Technology Inc.
MU, together with its subsidiaries, engages in the manufacture and marketing of semiconductor devices worldwide. Its products include dynamic random access memory (DRAM) products that provide data storage and retrieval, which include DDR, DDR2, DDR3, synchronous DRAM, and other specialty DRAM memory products, such as mobile DRAM, pseudo-static RAM, and reduced latency DRAM.
Idaho awards MU with a $5 million grant to help the company develop a line of energy efficient lighting products.
**************************************************************
Keep a close eye on CVAT, JNJ, CSRH, MRK, PWRM and MU do your homework, and like always BE READY for the ACTION!
***********Advertisement***********
********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.
Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for the completion of building a website for Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand shares of free trading stock from a third party for advertising services for Cavitation Technologies, Inc. (CVAT.OB) and an additional twenty-five thousand shares of 144 restricted stock from Cavitation Technologies, Inc. (CVAT.OB) for 12 months of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand dollars from Consorteum Holdings Inc. for 30 days of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has received 78,000 free trading and 500,000 144 (restricted) shares from a third party for 6 months of advertising services Consorteum Holdings Inc, (CSRH.OB)
_______________________________________________________
_______________________________________________________
Dr. Stock Pick
is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1000 websites www.crwenews.com, www.stock-ir.com giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com
email: investor@drstockpick.com
Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com
